search
Documents
Ph. Eur. Monograph 1573: Sumatriptan Succinate
Assay and Related Substances on SphereClone5 µm ODS(1) Column
In this application note we show the
separation of Sumatriptan
Succinate from its related substances following Ph. Eur. Monograph
1573. We used a SphereClone 5 µm ODS(1) column. To meet system
suitability requirements for Assay analysis, the percent RSD (%RSD)
must be a maximum of 0.73 % for Sumatriptan Succinate. To meet
system suitability requirements for Related Substances analysis, the
resolution must be a minimum of 1.5 between the peaks for
Impurity C and Sumatriptan Succinate. The SphereClone ODS(1)
column met system suitability requirements for both Assay and
Related Substances analysis.
Ph. Eur. Monograph 1573: Sumatriptan Succinate Assay and Related Substances on SphereClone5 µm ODS(1) Column
In this application note we show the
separation of Sumatriptan
Succinate from its related substances following Ph. Eur. Monograph
1573. We used a SphereClone 5 µm ODS(1) column. To meet system
suitability requirements for Assay analysis, the percent RSD (%RSD)
must be a maximum of 0.73 % for Sumatriptan Succinate. To meet
system suitability requirements for Related Substances analysis, the
resolution must be a minimum of 1.5 between the peaks for
Impurity C and Sumatriptan Succinate. The SphereClone ODS(1)
column met system suitability requirements for both Assay and
Related Substances analysis.
Document Type:
Technical Notes
Target Industries:
Techniques:
Brands:
Separation Modes:
Reversed Phase
Phases:
Ph. Eur. Monograph 1573: Sumatriptan Succinate Assay and Related Substances on SphereClone5 µm ODS(1) Column
In this application note we show the
separation of Sumatriptan
Succinate from its related substances following Ph. Eur. Monograph
1573. We used a SphereClone 5 µm ODS(1) column. To meet system
suitability requirements for Assay analysis, the percent RSD (%RSD)
must be a maximum of 0.73 % for Sumatriptan Succinate. To meet
system suitability requirements for Related Substances analysis, the
resolution must be a minimum of 1.5 between the peaks for
Impurity C and Sumatriptan Succinate. The SphereClone ODS(1)
column met system suitability requirements for both Assay and
Related Substances analysis.
| Target Industries: | Pharmaceutical |
| Techniques: | HPLC |
| Brands: | SphereClone |
| Separation Modes: | Reversed Phase |
| Phases: | SphereClone ODS(1) |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide